Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| ATTAIN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main purpose of this study is to assess the long term bronchodilator efficacy, safety and tolerability of inhaled aclidinium bromide at two dose levels compared to placebo in COPD patients and the benefits of the product in disease-related health status, COPD symptoms and COPD exacerbations.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Aclidinium bromide 200 μg bid | Experimental | Aclidinium bromide 200 μg twice-daily via inhalation |
|
| Aclidininum bromide 400 μg bid | Experimental | Aclidinium bromide 400 μg twice-daily via inhalation |
|
| Placebo | Placebo Comparator | Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Aclidinium bromide 200 μg bid | Drug | Aclidinium bromide 200 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in the First Second (FEV1) at Week 24 on Treatment | Baseline and Week 24 | |
| Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in the First Second (FEV1) at Week 12 on Treatment | Baseline and Week 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Peak Forced Expiratory Volume in the First Second (FEV1) at Week 24 on Treatment | Baseline and Week 24 | |
| Percentage of Patients Who Achieved at Least a 1-unit Decrease From Baseline in TDI Focal Score at Week 24 on Treatment | Number of patients achieving a clinically meaningful improvement (≥1-unit) in Transition Dyspnoea Index (TDI) focal score at Week 24 on Treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Esther Garcia, MD | AstraZeneca | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Almirall Investigational Sites#4 | Benešov | 256 01 | Czechia | |||
| Almirall Investigational Sites#9 |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28074135 | Derived | McGarvey L, Morice AH, Smith JA, Birring SS, Chuecos F, Seoane B, Jarreta D. Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials. BMJ Open Respir Res. 2016 Dec 8;3(1):e000148. doi: 10.1136/bmjresp-2016-000148. eCollection 2016. | |
| 27215749 | Derived | Jones PW, Leidy NK, Hareendran A, Lamarca R, Chuecos F, Garcia Gil E. The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies. Respir Res. 2016 May 23;17(1):61. doi: 10.1186/s12931-016-0372-1. |
| Label | URL |
|---|---|
| Almirall Corporate Website | View source |
Not provided
Patients fulfilling inclusion/exclusion criteria at the time of the Screening Visit were entered into a run-in period of 14±3 days to assess patient's disease stability.
This study was conducted at 103 sites (100/103 randomised patients), 10 sites in the Czech Republic, 5 in France, 17 in Germany, 13 in Hungary, 3 in Italy, 1 in Peru, 21 in Poland, 10 in the Russian Federation, 5 in Spain, 13 in South Africa and 5 in the Ukraine. The first patient was screened in Oct 2009 and the last patient visit was in Nov 2010.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Aclidinium Bromide 200 μg Bid | Aclidinium bromide 200 μg twice-daily via inhalation |
| FG001 | Aclidinium Bromide 400 μg Bid | Aclidinium bromide 400 μg twice-daily via inhalation |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Aclidinium bromide 400 μg bid | Drug | Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks |
|
| Placebo | Drug | Placebo twice-daily by inhalation for 24 weeks |
|
| Week 24 |
| Percentage of Patients Who Achieved at Least a 4-unit Decrease From Baseline in the SGRQ Total Score at Week 24 on Treatment | Number of patients who achieved a clinically meaningful improvement (≥4-units) in Saint George Respiratory Questionnaire (SGRQ) total score at week 24 on treatment | Week 24 |
| Jaroměř |
| 55 101 |
| Czechia |
| Almirall Investigational Sites#3 | Liberec | 460 01 | Czechia |
| Almirall Investigational Sites#2 | Lovosice | 410 02 | Czechia |
| Almirall Investigational Sites#1 | Neratovice | 277 11 | Czechia |
| Almirall Investigational Sites#11 | Prague | 158 00 | Czechia |
| Almirall Investigational Sites#6 | Prague | 158 00 | Czechia |
| Almirall Investigational Sites#12 | Prague | 163 00 | Czechia |
| Almirall Investigational Sites#7 | Prague | 169 00 | Czechia |
| Almirall Investigational Sites#10 | Strakonice | 386 01 | Czechia |
| Almirall Investigational Sites#3 | Clermont-Ferrand | 63003 | France |
| Almirall Investigational Sites#2 | Marseille | 13008 | France |
| Almirall Investigational Sites#1 | Marseille | 13915 | France |
| Almirall Investigational Sites#6 | Montpellier | 34295 | France |
| Almirall Investigational Sites#4 | Toulouse | 31059 | France |
| Almirall Investigational Sites#8 | Berlin | 10117 | Germany |
| Almirall Investigational Sites#9 | Berlin | 10969 | Germany |
| Almirall Investigational Sites#6 | Berlin | 13125 | Germany |
| Almirall Investigational Sites#14 | Berlin | 13507 | Germany |
| Almirall Investigational Site#7 | Berlin | 14057 | Germany |
| Almirall Investigational Sites#12 | Bonn | 53123 | Germany |
| Almirall Investigational Sites#10 | Cologne | 51069 | Germany |
| Almirall Investigational Sites#3 | Dortmund | 44263 | Germany |
| Almirall Investigational Sites#13 | Frankfurt | 60596 | Germany |
| Almirall Investigational Sites#15 | Gelsenkirchen | 45879 | Germany |
| Almirall Investigational Sites#1 | Großhansdorf | 22927 | Germany |
| Almirall Investigational Sites#5 | Hamburg | 20249 | Germany |
| Almirall Investigational Sites#4 | Hamburg | 22143 | Germany |
| Almirall Investigational Site#16 | Hanover | 30159 | Germany |
| Almirall Investigational Sites#18 | Jena | 07743 | Germany |
| Almirall Investigational Sites#11 | Mainz | 55131 | Germany |
| Almirall Investigational Site#2 | Rüdersdorf | 15562 | Germany |
| Almirall Investigational Sites#13 | Budapest | 1036 | Hungary |
| Almirall Investigational Sites#4 | Budapest | 1046 | Hungary |
| Almirall Investigational Sites#1 | Budapest | 1125 | Hungary |
| Almirall Investigational Sites#2 | Budapest | 1529 | Hungary |
| Almirall Investigational Sites#6 | Debrecen | 4032 | Hungary |
| Almirall Investigational Sites#5 | Debrecen | 4043 | Hungary |
| Almirall Investigational Sites#7 | Deszk | 6772 | Hungary |
| Almirall Investigational Sites#10 | Dunaüjváros | 2400 | Hungary |
| Almirall Investigational Sites#9 | Mátraháza | 3233 | Hungary |
| Almirall Investigational Sites#12 | Pécs | 7621 | Hungary |
| Almirall Investigational Sites#11 | Ráckeve | 2300 | Hungary |
| Almirall Investigational Sites#3 | Százhalombatta | 2440 | Hungary |
| Almirall Investigational Sites#8 | Zalaegerszeg | 8900 | Hungary |
| Almirall Investigational Sites#3 | Cagliari | 09126 | Italy |
| Almirall Investigational Sites#1 | Genova | 16132 | Italy |
| Almirall Investigational Sites#10 | Pisa | 56124 | Italy |
| Almirall Investigational Sites#8 | Cusco | Peru |
| Almirall Investigational Sites#12 | Bialystok | 15-003 | Poland |
| Almirall Investigational Sites#9 | Bialystok | 15-540 | Poland |
| Almirall Investigational Sites#19 | Elblag | 82-307 | Poland |
| Almirall Investigational Sites#18 | Gdansk | 80-211 | Poland |
| Almirall Investigational Sites#20 | Iława | 14-200 | Poland |
| Almirall Investigational Sites#7 | Lodz | 90-430 | Poland |
| Almirall Investigational Sites#1 | Lodz | 91-153 | Poland |
| Almirall Investigational Sites#8 | Lublin | Poland |
| Almirall Investigational Sites#24 | Olsztyn | 10-357 | Poland |
| Almirall Investigational Sites#5 | Olsztyn | 10-357 | Poland |
| Almirall Investigational Sites#21 | Poznan | 60-214 | Poland |
| Almirall Investigational Sites#16 | Poznan | 60-693 | Poland |
| Almirall Investigational Site#11 | Proszowice | 32-100 | Poland |
| Almirall Investigational Sites#2 | Ruda Śląska | 41-709 | Poland |
| Almirall Investigational Sites#13 | Rudka | 05-320 | Poland |
| Almirall Investigational Sites#4 | Sopot | 81-741 | Poland |
| Almirall Investigational Sites#14 | Szczecin | 70-111 | Poland |
| Almirall Investigational Sites#15 | Tarnów | 33-100 | Poland |
| Almirall Investigational Sites#6 | Tarnów | 33-100 | Poland |
| Almirall Investigational Sites#25 | Warsaw | 01-138 | Poland |
| Almirall Investigational Sites#23 | Wilkowice-Bystra | 43-365 | Poland |
| Almirall Investigational Site#10 | Wroclaw | 50-349 | Poland |
| Almirall Investigational Sites#5 | Kazan' | 420015/420103 | Russia |
| Almirall Investigational Sites#2 | Moscow | 115446 | Russia |
| Almirall Investigational Sites#14 | Moscow | 123182 | Russia |
| Almirall Investigational Sites#6 | Moscow | 127018/127473 | Russia |
| Almirall Investigational Sites#13 | Novosibirsk | 630008 | Russia |
| Almirall Investigational Sites#10 | Saint Petersburg | 194354 | Russia |
| Almirall Investigational Sites#3 | Saint Petersburg | 197022 | Russia |
| Almirall Investigational Sites#4 | Saint Petersburg | 197089/197022 | Russia |
| Almirall Investigational Sites#8 | Tomsk | 634050/634034 | Russia |
| Almirall Investigational Sites#12 | Tomsk | 634050 | Russia |
| Almirall Investigational Sites#7 | Yekaterinburg | 620219 / 620109 | Russia |
| Almirall Investigational Sites#8 | Bloemfontein | 9300 | South Africa |
| Almirall Investigational Sites#11 | Bloemfontein | 9301 | South Africa |
| Almirall Investigational Sites#3 | Bloemfontein | 9301 | South Africa |
| Almirall Investigational Sites#10 | Cape Town | 7500 | South Africa |
| Almirall Investigational Sites#1 | Cape Town | 7505 | South Africa |
| Almirall Investigational Sites#12 | Cape Town | South Africa |
| Almirall Investigational Sites#15 | Cape Town | South Africa |
| Almirall Investigational Sites#2 | Durban | South Africa |
| Almirall Investigational Sites#9 | George | 6529 | South Africa |
| Almirall Investigational Sites#4 | Port Elizabeth | 6045 | South Africa |
| Almirall Investigational Sites#5 | Pretoria | 0002 | South Africa |
| Almirall Investigational Sites#14 | Pretoria | 0081 | South Africa |
| Almirall Investigational Sites#6 | Pretoria | 181 | South Africa |
| Almirall Investigational Sites#6 | Badalona | 08916 | Spain |
| Almirall Investigational Sites#8 | Barcelona | 08035 | Spain |
| Almirall Investigational Sites#7 | Barcelona | 08036 | Spain |
| Almirall Investigational Sites#3 | Madrid | 28041 | Spain |
| Almirall Investigational Sites#5 | Valencia | 46015 | Spain |
| Almirall Investigational Sites#4 | Donetsk | 83099 | Ukraine |
| Almirall Investigational Sites#3 | Kharkiv | 61001 | Ukraine |
| Almirall Investigational Sites#1 | Kyiv | 03680 | Ukraine |
| Almirall Investigational Sites#2 | Kyiv | 03680 | Ukraine |
| Almirall Investigational Sites#7 | Kyiv | 04050 | Ukraine |
| Almirall Investigational Sites#5 | Zaporizhzhya | 69118 | Ukraine |
| 25234803 | Derived | Jones PW, Lamarca R, Chuecos F, Singh D, Agusti A, Bateman ED, de Miquel G, Caracta C, Garcia Gil E. Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J. 2014 Nov;44(5):1156-65. doi: 10.1183/09031936.00038814. Epub 2014 Sep 18. |
| 22441743 | Derived | Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, Segarra R, Caracta C, Garcia Gil E. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012 Oct;40(4):830-6. doi: 10.1183/09031936.00225511. Epub 2012 Mar 22. |
| FG002 | Placebo | Placebo via inhalation |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Aclidinium Bromide 200 μg Bid | Aclidinium bromide 200 μg twice-daily via inhalation |
| BG001 | Aclidinium Bromide 400 μg Bid | Aclidinium bromide 400 μg twice-daily via inhalation |
| BG002 | Placebo | Placebo via inhalation |
| BG003 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Gender | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in the First Second (FEV1) at Week 24 on Treatment | Intention-to-treat (ITT) population: all randomised patients who took at least one dose of Investigational Medicinal Product and who had a baseline and at least 1 post-baseline FEV1 assessment. | Posted | Least Squares Mean | Standard Error | Liters | Baseline and Week 24 |
|
|
| ||||||||||||||||||||||||||||||||
| Primary | Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in the First Second (FEV1) at Week 12 on Treatment | Intention-to-treat (ITT) population: all randomised patients who took at least one dose of Investigational Medicinal Product and who had a baseline and at least 1 post-baseline FEV1 assessment. | Posted | Least Squares Mean | Standard Error | Liters | Baseline and Week 12 |
|
| |||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Peak Forced Expiratory Volume in the First Second (FEV1) at Week 24 on Treatment | Intention-to-treat (ITT) population: all randomised patients who took at least one dose of Investigational Medicinal Product and who had a baseline and at least 1 post-baseline FEV1 assessment. | Posted | Least Squares Mean | Standard Error | Liters | Baseline and Week 24 |
|
| |||||||||||||||||||||||||||||||||
| Secondary | Percentage of Patients Who Achieved at Least a 1-unit Decrease From Baseline in TDI Focal Score at Week 24 on Treatment | Number of patients achieving a clinically meaningful improvement (≥1-unit) in Transition Dyspnoea Index (TDI) focal score at Week 24 on Treatment | Intention-to-treat (ITT) population: all randomised patients who took at least one dose of Investigational Medicinal Product and who had a baseline and at least 1 post-baseline FEV1 assessment. | Posted | Number | Percentage of participants | Week 24 |
|
| |||||||||||||||||||||||||||||||||
| Secondary | Percentage of Patients Who Achieved at Least a 4-unit Decrease From Baseline in the SGRQ Total Score at Week 24 on Treatment | Number of patients who achieved a clinically meaningful improvement (≥4-units) in Saint George Respiratory Questionnaire (SGRQ) total score at week 24 on treatment | Intention-to-treat (ITT) population: all randomised patients who took at least one dose of Investigational Medicinal Product and who had a baseline and at least 1 post-baseline FEV1 assessment. | Posted | Number | Percentage of participants | Week 24 |
|
|
24 Weeks
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Aclidinium Bromide 200 μg Bid | Aclidinium bromide 200 μg twice-daily via inhalation | 12 | 277 | 44 | 277 | ||
| EG001 | Aclidinium Bromide 400 μg Bid | Aclidinium bromide 400 μg twice-daily via inhalation | 15 | 269 | 38 | 269 | ||
| EG002 | Placebo | Placebo via inhalation | 15 | 273 | 56 | 273 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Chronic Obstructive Pulmonary Disease | Respiratory, thoracic and mediastinal disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Pneumothorax | Respiratory, thoracic and mediastinal disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Acute Pulmonary Oedema | Respiratory, thoracic and mediastinal disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Myocardial ischaemia | Cardiac disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Angina Pectoris | Cardiac disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Cardiac discomfort | Cardiac disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Cardiac failure acute | Cardiac disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Cardiac failure congestive | Cardiac disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Sick sinus syndrome | Cardiac disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Left vetricular failure | Cardiac disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Myocardial infarction | Cardiac disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Ligament ruptures | Injury, poisoning and procedural complications | MedDRA (13.1) | Systematic Assessment |
| |
| Rib fracture | Injury, poisoning and procedural complications | MedDRA (13.1) | Systematic Assessment |
| |
| Road traffic accident | Injury, poisoning and procedural complications | MedDRA (13.1) | Systematic Assessment |
| |
| Tibia fracture | Injury, poisoning and procedural complications | MedDRA (13.1) | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA (13.1) | Systematic Assessment |
| |
| Bronchopneumonia | Infections and infestations | MedDRA (13.1) | Systematic Assessment |
| |
| Pulmonary tuberculosis | Infections and infestations | MedDRA (13.1) | Systematic Assessment |
| |
| Bladder transitional cell carcinoma stage III | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (13.1) | Systematic Assessment |
| |
| Mycosis fungoides | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (13.1) | Systematic Assessment |
| |
| Benign lung neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (13.1) | Systematic Assessment |
| |
| Pancreatic neuroendocrine tumour | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (13.1) | Systematic Assessment |
| |
| Bursitis | Musculoskeletal and connective tissue disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Musculoskeletal pain | Musculoskeletal and connective tissue disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Invertebral disc protrusion | Musculoskeletal and connective tissue disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Arteriosclerosis | Vascular disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Aortis stenosis | Vascular disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Subclavian atery stenosis | Vascular disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Cerebral haemorrhage | Nervous system disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Demyelinating polyneuropathy | Nervous system disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Iron deficiency anaemia | Blood and lymphatic system disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Mixed deafness | Ear and labyrinth disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Subileus | Gastrointestinal disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Cholecystitis | Hepatobiliary disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Completed suicide | Psychiatric disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Nephrolithiasis | Renal and urinary disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Erythema nodosum | Skin and subcutaneous tissue disorders | MedDRA (13.1) | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Chronic obstructivce pulmonary disease | Respiratory, thoracic and mediastinal disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA (13.1) | Systematic Assessment |
|
All the information related to this clinical trial is considered strictly confidential and is the property of Almirall. This information will not be given to a third party without the written consent of Almirall. Publication and/or presentation, whether complete or partial, of any part of the data or results of this trial will be subject to revision and written agreement between the investigator and Almirall.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| AstraZeneca Clinical | Study Information Center | 1-877-240-9479 | information.center@astrazeneca.com |
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C542859 | aclidinium bromide |
| C494814 | BID protein, human |
Not provided
Not provided
Not provided
| Between 18 and 65 years |
|
| >=65 years |
|
| Male |
|
| Ukraine |
|
| Russian Federation |
|
| Italy |
|
| France |
|
| Hungary |
|
| Czech Republic |
|
| Poland |
|
| South Africa |
|
| Germany |
|
|
|
|
|
|